USPTO serial 79068784
GLYCOEXPRESS
Reviewed by CopyMark Law Group
Reg. 3991708Status 709
- Filing date
- Status date
- Registration date
- Jul 12, 2011
- Examiner
- LEE, DEBRA ANN
- Law office
- —
What this means
This page summarizes the public USPTO record for this serial number, including owners, goods and services, and prosecution history.
Need help with GLYCOEXPRESS?
If you own this trademark, we can monitor new filings and help with USPTO deadlines. If you do not, we can file a new U.S. application.
Current trademark owner
Monitor this mark, or talk with CopyMark about this registration.
Not the owner?
File a new U.S. trademark application, or speak with our attorneys.
Owner
Attorney of record
The USPTO lists this attorney as the applicant's representative for correspondence on this application.
GARY D. KRUGMAN
GARY D. KRUGMAN SUGHRUE MION, PLLC2000 Pennsylvania Avenue NW, Suite 900Washington, DC 20006UNITED STATESGoods and services
| Class | Description | Status | First use |
|---|---|---|---|
| 001 | [Chemicals used in industry, science and photography, as well as in agriculture, horticulture and forestry, except fungicides, herbicides, insecticides and parasiticides; unprocessed artificial resins; unprocessed plastics; fertilizing preparations; fire extinguishing compositions; tempering and soldering chemicals; chemical substances for fermenting and preserving food stuffs; tanning agents for use in the manufacture of leather; adhesives used in industry; bacteria and cell preparations and elements, fragments, fractions and lysates thereof, except for medical or veterinary purposes, namely, for use in protein production, food manufacturing, scientific research, waste water treatment, bacteria and cell preparations for use in expression of engineered or glycosylated proteins and peptides; preparations containing bacteria and cells, except for medical or veterinary purposes, namely, for use in protein production, food manufacturing, scientific research, waste water treatment; biological preparations for laboratories, except for medical or veterinary purposes, namely, for use in bacterial and cell engineering, cultivation, harvesting, protein production; chemical preparations for analysis in laboratories, namely, preparations for protein, peptide, engineered proteins and peptides, glycoproteins, glycosylation, antibody or antigen analysis, preparations comprising antibody reagents used for the detection of antigens; chemical preparations for scientific purposes; chemical reagents except for medical or veterinary purposes and biological reagents in the nature of reagents for use in protein production, bacterial and cell engineering, cultivation and harvesting, probes for detecting and analyzing molecules in protein or nucleotide arrays, except for medical or veterinary purposes; diagnostic preparations, except for medical or veterinary purposes; enzymes, proteins and respective preparations for industrial purposes, namely, engineered proteins, glycosylated proteins, antibodies, enzymes for use in glycosylation, enzyme substrates, proteins used in the manufacture of cosmetics, beverages, food products and food supplements; ferments for chemical purposes, namely, yeast, bacterium, mold, or enzyme, that causes fermentation; in-vitro diagnostic preparations, other than for medical purposes; carbohydrates used as an ingredient or as an integral component in food or nutraceuticals; cultures of microorganisms and cells and elements, fragments, fractions and lysates thereof, other than for medical or veterinary purposes, namely, cultures of microorganisms and cells other than for medical and veterinary use, microorganism or cell cultures for use in protein production, food manufacturing, scientific research, waste water treatment, cultures of microorganisms or cells for use in expression of glycosylated proteins and peptides; gene expression systems for proteins and peptides, particularly on the basis of cells, particularly human cells and microorganisms, namely, gene expression systems comprising biochemicals, assays, and reagents for use in manufacturing engineered or glycosylated proteins or peptides and for scientific research, gene expression systems comprising biochemicals, assays and reagents with optimized glycosylation activity for use in manufacturing proteins or peptides, in particular engineered or glycosylated proteins or peptides, and for scientific research; milk ferments for medical research purposes] | SECTION 71 - CANCELLED | — |
| 005 | [Pharmaceutical and veterinary preparations for prophylaxis or treatment of cancer, inflammatory diseases, autoimmune diseases, allergies, cardiovascular diseases, infectious diseases, neurological diseases, gastrointestinal diseases, and for use in wound healing, formation of blood and tissue and reproduction medicine; sanitary preparations for medical purposes; dietetic foods adapted for medical use; food for babies; medical plasters; materials for medical dressings; disinfectants for sanitary purposes; preparations for destroying vermin; fungicides, herbicides; adjuvants for medical purposes; medicines for human and veterinary purposes for prophylaxis or treatment of cancer, inflammatory diseases, autoimmune diseases, allergies, cardiovascular diseases, infectious diseases, neurological diseases, gastrointestinal diseases, and for use in wound healing, formation of blood and tissue and reproduction medicine; biological preparations for medical purposes; dietetic food adapted for medical purposes; enzyme, proteins, antibodies, cells, microorganisms as well as fragments, fractions, elements and lysates thereof for medical purposes for prophylaxis or treatment of cancer, inflammatory diseases, autoimmune diseases, allergies, cardiovascular diseases, infectious diseases, neurological diseases, gastrointestinal diseases, and for use in wound healing, formation of blood and tissue and reproduction medicine, and as nutritional additives for medical purposes for use in foods and dietary supplements for human consumption; vaccines; carbohydrates for medical purposes for prophylaxis or treatment of cancer, inflammatory diseases, autoimmune diseases, allergies, cardiovascular diseases, infectious diseases, neurological diseases, gastrointestinal diseases, and for use in wound healing, formation of blood and tissue and reproduction medicine; cultures of microorganisms for medical or veterinary purposes for prophylaxis or treatment of cancer, inflammatory diseases, autoimmune diseases, allergies, cardiovascular diseases, infectious diseases, neurological diseases, gastrointestinal diseases, and for use in wound healing, formation of blood and tissue and reproduction medicine; cultures of human cells for medical or veterinary purposes for prophylaxis or treatment of cancer, inflammatory diseases, autoimmune diseases, allergies, cardiovascular diseases, infectious diseases, neurological diseases, gastrointestinal diseases, and for use in wound healing, formation of blood and tissue and reproduction medicine; medical drinks for prophylaxis or treatment of cancer, inflammatory diseases, autoimmune diseases, allergies, cardiovascular diseases, infectious diseases, neurological diseases, gastrointestinal diseases, and for use in wound healing, formation of blood and tissue and reproduction medicine; microorganisms, cells and preparations containing elements, fragments, fractions and lysates of microorganisms or cells for medical and veterinary purposes for prophylaxis or treatment of cancer, inflammatory diseases, autoimmune diseases, allergies, cardiovascular diseases, infectious diseases, neurological diseases, gastrointestinal diseases, and for use in wound healing, formation of blood and tissue and reproduction medicine; biological therapeutics, namely, therapeutics containing cells, microorganisms, proteins, glycoproteins, peptides, glycopeptides or modified or conjugated versions thereof for use in the prophylaxis or treatment of cancer, inflammatory diseases, autoimmune diseases, allergies, cardiovascular diseases, infectious diseases, neurological diseases, gastrointestinal diseases, and for use in wound healing, formation of blood and tissue and reproduction medicine; milk ferments for pharmaceutical purposes for prophylaxis or treatment of cancer, inflammatory diseases, autoimmune diseases, allergies, cardiovascular diseases, infectious diseases, neurological diseases, gastrointestinal diseases, and for use in wound healing, formation of blood and tissue and reproduction medicine; nutritional additives and nutritional supplement additives for medical purposes for use in foods and dietary supplements for human consumption; nutrients for medical purposes for human or animals, namely, nutritional additives in the nature of enzymes, proteins, antibodies, cells, microorganisms as well as fragments, fractions, elements and lysates thereof; sugar and carbohydrates for medical purposes, namely, therapeutically and prophylactically active sugar and carbohydrates, dietetic sugar and carbohydrates, sugar and carbohydrate replacements] | SECTION 71 - CANCELLED | — |
| 042 | Scientific and technological services, namely, [bacteria and] cell engineering services, [bacteria and] cell cultivation and harvesting services, research and development related to protein production, glycosylation, optimization of protein, antibody and enzyme activity, [bacteria and] cell engineering, cultivation and harvesting; research and design services in the field of biotechnology, protein production, glycosylation, optimization of protein, antibody and enzyme activity, [bacteria and] cell engineering, cultivation and harvesting; industrial analysis and research services in the field of biotechnology, protein production, glycosylation, protein, antibody and enzyme activity, [bacteria and] cell engineering, cultivation and harvesting; [design and development of computer hardware and software;] biological research; services of a [chemical or] biological laboratory; [technical surveys, namely, conducting biotechnology surveys, pharmacology surveys; conducting scientific surveys in the field of biotechnology, bacterial and cell engineering, protein production, glycosylation;] research and development in the field of [bacteriology, ]cytology, antibody technology, [chemistry, immunology, cosmetics of expression systems in the nature of glycosylation of proteins, peptides, antibodies and enzymes, particularly for proteins and peptides; quality control;] research and development of new products and technologies in the field of biotechnology, protein production, glycosylation, protein, antibody and enzyme activity,[ bacteria and] cell engineering, cultivation and harvesting for others; technology and scientific consultancy in the field of biotechnology, protein production, glycosylation, protein, antibody and enzyme activity, [bacteria and] cell engineering, cultivation and harvesting; research and development in the field of glycomics, expression systems in the nature of glycosylation of proteins, peptides, antibodies and enzymes, development and improvement of cells, cell lines [and microorganisms,] antibody-engineering, optimized biological therapeutics; [nutraceuticals, and food and nutritional supplements;] research, [quality control,] technology consultancy and product development in the field of proteins, antibodies, [microorganisms] and cells; research and development in the field of [microorganisms and] cells | SECTION 71 - CANCELLED | — |
Related trademarks
CopyMark links this record to cited §2(d) serials, the owner's other marks, Nice classes, similar mark names, and recently changed USPTO applications.
- Other trademarks owned by Glycotope GmbH
- Other trademarks owned by Glycotope GmbH
- Other trademarks owned by Glycotope GmbH
- Other trademarks in Class 001
- Other trademarks in Class 005
- Other trademarks in Class 042
- Similar marks named GLYCOEXPRESS
- Recently changed USPTO trademarks
- Recently filed trademarks
- Browse all trademark records
Prosecution history
| Date | Code | Event | What it means |
|---|---|---|---|
| Nov 6, 2022 | INNT | TOTAL INVALIDATION PROCESSED BY THE IB | — |
| Oct 6, 2022 | INTS | TOTAL INVALIDATION OF REG EXT PROTECTION SENT TO IB | — |
| Oct 6, 2022 | INPC | INVALIDATION PROCESSED | — |
| Sep 28, 2022 | INTR | TOTAL INVALIDATION OF REG EXT PROTECTION CREATED | — |
| Jan 28, 2022 | C71T | CANCELLED SECTION 71 | — |
| Jul 12, 2020 | REM4 | COURTESY REMINDER - SEC. 71 (10-YR) E-MAILED | — |
| Dec 16, 2019 | ARAA | ATTORNEY/DOM.REP.REVOKED AND/OR APPOINTED | This event means the applicant filed a response to a USPTO Office Action — typically arguments, amendments, or evidence addressing the examiner's objections. The USPTO will review the response and either allow the mark to proceed or issue another action. |
| Dec 16, 2019 | REAP | TEAS REVOKE/APP/CHANGE ADDR OF ATTY/DOM REP RECEIVED | — |
| Dec 27, 2018 | RNWL | INTERNATIONAL REGISTRATION RENEWED | — |
| Oct 19, 2018 | INNP | PARTIAL INVALIDATION PROCESSED BY THE IB | — |
| Sep 13, 2018 | INPS | PARTIAL INVALIDATION OF REG EXT PROTECTION SENT TO IB | — |
| Sep 13, 2018 | INPC | INVALIDATION PROCESSED | — |
| Sep 3, 2018 | INPR | PARTIAL INVALIDATION OF REG EXT PROTECTION CREATED | — |
| Jul 27, 2017 | NA75 | NOTICE OF ACCEPTANCE OF SEC. 71 & 15 - E-MAILED | — |
| Jul 27, 2017 | C75P | REGISTERED - PARTIAL SEC. 71 ACCEPTED & SEC. 15 ACK. | — |
| Jul 22, 2017 | APRE | CASE ASSIGNED TO POST REGISTRATION PARALEGAL | — |
| Jul 6, 2017 | ES75 | TEAS SECTION 71 & 15 RECEIVED | — |
| Dec 14, 2013 | NREP | NEW REPRESENTATIVE AT IB RECEIVED | — |
| Mar 3, 2013 | FINO | FINAL DECISION TRANSACTION PROCESSED BY IB | — |
| Jan 6, 2012 | FICS | FINAL DISPOSITION NOTICE SENT TO IB | — |
| Jan 5, 2012 | FIMP | FINAL DISPOSITION PROCESSED | — |
| Oct 12, 2011 | FICR | FINAL DISPOSITION NOTICE CREATED, TO BE SENT TO IB | — |
| Jul 12, 2011 | R.PR | REGISTERED-PRINCIPAL REGISTER | Your trademark is registered on the Principal Register — the strongest form of federal trademark protection. You may use the ® symbol for the covered goods and services. Maintenance filings (Section 8 and renewals) are required to keep the registration alive. |
| Apr 26, 2011 | NPUB | OFFICIAL GAZETTE PUBLICATION CONFIRMATION E-MAILED | — |
| Apr 26, 2011 | PUBO | PUBLISHED FOR OPPOSITION | Your mark was published in the USPTO Official Gazette for a 30-day opposition window. During that period, third parties who believe they would be harmed can file an opposition. If no opposition is filed, prosecution usually continues toward registration or a Notice of Allowance. |
| Apr 23, 2011 | OPNX | NOTIFICATION OF POSSIBLE OPPOSITION - PROCESSED BY IB | — |
| Apr 6, 2011 | OPNS | NOTIFICATION OF POSSIBLE OPPOSITION SENT TO IB | — |
| Apr 6, 2011 | OP2R | NOTICE OF START OF OPPOSITION PERIOD CREATED, TO BE SENT TO IB | — |
| Mar 22, 2011 | PREV | LAW OFFICE PUBLICATION REVIEW COMPLETED | — |
| Mar 22, 2011 | EXPT | EXPARTE APPEAL TERMINATED | — |
| Mar 21, 2011 | CNSA | APPROVED FOR PUB - PRINCIPAL REGISTER | — |
| Mar 21, 2011 | XAEC | EXAMINER'S AMENDMENT ENTERED | — |
| Mar 21, 2011 | GNEN | NOTIFICATION OF EXAMINERS AMENDMENT E-MAILED | — |
| Mar 21, 2011 | GNEA | EXAMINERS AMENDMENT E-MAILED | — |
| Mar 21, 2011 | CNEA | EXAMINERS AMENDMENT -WRITTEN | — |
| Mar 11, 2011 | GEA1 | NOTIFICATION OF ACTION DENYING REQ FOR RECON E-MAILED | — |
| Mar 11, 2011 | GECD | ACTION DENYING REQ FOR RECON E-MAILED | — |
| Mar 11, 2011 | CNCF | ACTION CONTINUING FINAL - COMPLETED | — |
| Mar 5, 2011 | OPNX | NOTIFICATION OF POSSIBLE OPPOSITION - PROCESSED BY IB | — |
| Feb 17, 2011 | OPNS | NOTIFICATION OF POSSIBLE OPPOSITION SENT TO IB | — |
| Feb 17, 2011 | OPNR | NOTIFICATION OF POSSIBLE OPPOSITION CREATED, TO BE SENT TO IB | — |
| Feb 14, 2011 | EXPI | EX PARTE APPEAL-INSTITUTED | — |
| Feb 14, 2011 | JURT | JURISDICTION RESTORED TO EXAMINING ATTORNEY | — |
| Feb 14, 2011 | EXAF | EXPARTE APPEAL RECEIVED AT TTAB | — |
| Feb 2, 2011 | TEME | TEAS/EMAIL CORRESPONDENCE ENTERED | — |
| Feb 2, 2011 | CRFA | CORRESPONDENCE RECEIVED IN LAW OFFICE | — |
| Jan 31, 2011 | ALIE | ASSIGNED TO LIE | — |
| Jan 31, 2011 | ERFR | TEAS REQUEST FOR RECONSIDERATION RECEIVED | — |
| Oct 28, 2010 | ARAA | ATTORNEY/DOM.REP.REVOKED AND/OR APPOINTED | This event means the applicant filed a response to a USPTO Office Action — typically arguments, amendments, or evidence addressing the examiner's objections. The USPTO will review the response and either allow the mark to proceed or issue another action. |
| Oct 28, 2010 | REAP | TEAS REVOKE/APP/CHANGE ADDR OF ATTY/DOM REP RECEIVED | — |
| Aug 12, 2010 | CNFR | FINAL REFUSAL MAILED | A final Office Action (final refusal) means the examining attorney is maintaining at least one refusal and your options are narrower. You can file a response addressing the refusal, appeal to the Trademark Trial and Appeal Board, or let the application abandon. |
| Aug 11, 2010 | CNFR | FINAL REFUSAL WRITTEN | A final Office Action (final refusal) means the examining attorney is maintaining at least one refusal and your options are narrower. You can file a response addressing the refusal, appeal to the Trademark Trial and Appeal Board, or let the application abandon. |
| Jul 27, 2010 | TEME | TEAS/EMAIL CORRESPONDENCE ENTERED | — |
| Jan 21, 2010 | LIMN | LIMITATION FROM THE IB EXAMINED, NO ACTION IS NEEDED | — |
| Jan 21, 2010 | LIMG | LIMITATION OF GOODS RECEIVED FROM IB | — |
| Jan 5, 2010 | LIMS | LIMITATION OF GOODS/SERVICES FROM IB ENTERED | — |
| Dec 22, 2009 | CRFA | CORRESPONDENCE RECEIVED IN LAW OFFICE | — |
| Dec 22, 2009 | TROA | TEAS RESPONSE TO OFFICE ACTION RECEIVED | This event means the applicant filed a response to a USPTO Office Action — typically arguments, amendments, or evidence addressing the examiner's objections. The USPTO will review the response and either allow the mark to proceed or issue another action. |
| Nov 30, 2009 | LIMG | LIMITATION OF GOODS RECEIVED FROM IB | — |
| Oct 17, 2009 | ATRV | ATTORNEY REVIEW COMPLETED | — |
| Sep 25, 2009 | CREV | CORRECTION FROM IB ENTERED - ATTORNEY REVIEW REQUIRED | — |
| Sep 19, 2009 | RFNP | REFUSAL PROCESSED BY IB | — |
| Sep 18, 2009 | CRCV | CORRECTION TRANSACTION RECEIVED FROM IB | — |
| Jun 26, 2009 | RFCS | NON-FINAL ACTION MAILED - REFUSAL SENT TO IB | — |
| Jun 26, 2009 | RFRR | REFUSAL PROCESSED BY MPU | — |
| Jun 26, 2009 | RFCR | NON-FINAL ACTION (IB REFUSAL) PREPARED FOR REVIEW | — |
| Jun 25, 2009 | CNRT | NON-FINAL ACTION WRITTEN | A non-final Office Action means the USPTO examining attorney has raised at least one issue with your trademark application but has not made a final decision. You usually have three months to respond with arguments, amendments, or evidence. Missing the deadline can abandon the application. |
| Jun 23, 2009 | MAFR | APPLICATION FILING RECEIPT MAILED | — |
| Jun 19, 2009 | DOCK | ASSIGNED TO EXAMINER | — |
| Jun 19, 2009 | NWOS | NEW APPLICATION OFFICE SUPPLIED DATA ENTERED | — |
| Jun 18, 2009 | REPR | SN ASSIGNED FOR SECT 66A APPL FROM IB | — |